{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T18:18:50Z","timestamp":1766600330664,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.clbc.2023.06.013","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T02:45:25Z","timestamp":1688697925000},"page":"712-720.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting"],"prefix":"10.1016","volume":"23","author":[{"given":"Raffaella","family":"D'Onofrio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Omarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Toss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Sperduti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Piacentini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Barbolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Cortesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Pettorelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Chiavelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Dominici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9108-4849","authenticated-orcid":false,"given":"Luca","family":"Moscetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clbc.2023.06.013_bib0001","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clbc.2023.06.013_bib0002","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1159\/000439462","article-title":"The modern landscape of endocrine therapy for premenopausal women with breast cancer","volume":"10","author":"Rossi","year":"2015","journal-title":"Breast Care"},{"issue":"5","key":"10.1016\/j.clbc.2023.06.013_bib0003","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJMoa1412379","article-title":"SOFT Investigators; International Breast Cancer Study Group. Adjuvant ovarian suppression in premenopausal breast cancer","volume":"372","author":"Francis","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2023.06.013_bib0004","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1404037","article-title":"TEXT and SOFT Investigators; International Breast Cancer Study Group Adjuvant exemestane with ovarian suppression in premenopausal breast cancer","volume":"371","author":"Pagani","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clbc.2023.06.013_bib0005","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1404037","article-title":"TEXT and SOFT Investigators; International Breast Cancer Study GroupAdjuvant exemestane with ovarian suppression in premenopausal breast cancer","volume":"371","author":"Pagani","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clbc.2023.06.013_bib0006","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1803164","article-title":"SOFT and TEXT Investigators and the International Breast Cancer Study Group Tailoring adjuvant endocrine therapy for premenopausal breast cancer","volume":"379","author":"Francis","year":"2018","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.clbc.2023.06.013_bib0007","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1200\/JCO.2015.64.3171","article-title":"Gelber RD.Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials","volume":"34","author":"Regan","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2023.06.013_bib0008","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","article-title":"American Society of Clinical Oncology \/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","volume":"28","author":"Hammond","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clbc.2023.06.013_bib0009","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.lungcan.2009.02.024","article-title":"A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer","volume":"66","author":"Bria","year":"2009","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1016\/j.clbc.2023.06.013_bib0010","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to event outcomes: reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"issue":"9","key":"10.1016\/j.clbc.2023.06.013_bib0011","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"19","key":"10.1016\/j.clbc.2023.06.013_bib0012","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2023.06.013_bib0013","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1200\/JCO.2015.65.9573","article-title":"Griggs JJ.Adjuvant endocrine therapy for women with hormone receptor\u2013positive breast cancer: American Society of Clinical Oncology clinical practice guideline update on ovarian suppression","volume":"34","author":"Burstein","year":"2016","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clbc.2023.06.013_bib0014","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.annonc.2022.07.007","article-title":"ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)","volume":"33","author":"Paluch-Shimon","year":"2022","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.clbc.2023.06.013_bib0015","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1158\/1078-0432.CCR-20-3974","article-title":"Early discontinuation of endocrine therapy and recurrence of breast cancer among premenopausal women","volume":"27","author":"Collin","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.clbc.2023.06.013_bib0016","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMoa2212856","article-title":"POSITIVE Trial Collaborators. Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer","volume":"388","author":"Partridge","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2023.06.013_bib0017","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"ABCSG-12 Trial Investigators; Endocrine therapy plus Zolendronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2023.06.013_bib0018","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s12885-016-2354-6","article-title":"The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): study protocol for a randomized controlled trial and progress","volume":"16","author":"Kim","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clbc.2023.06.013_bib0019","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group.Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"issue":"suppl 18","key":"10.1016\/j.clbc.2023.06.013_bib0020","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/jco.2013.31.18_suppl.5","article-title":"aTTom: long-term effects of adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer","volume":"31","author":"Gray","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2023.06.013_bib0021","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1158\/1538-7445.SABCS18-P4-14-01","article-title":"Abstract P4-14-01: estrogen levels in premenopausal patients (pts) with hormone-receptor positive (HR\u00fe) early breast cancer (BC) receiving adjuvant triptorelin (Trip) plus exemestane (E) or tamoxifen (T) in the SOFT trial: SOFT-EST substudy final analysis","volume":"79","author":"Bellet","year":"2019","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.clbc.2023.06.013_bib0022","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.annonc.2021.09.015","article-title":"monarchE Committee MembersAdjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study","volume":"32","author":"Harbeck","year":"2021","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.clbc.2023.06.013_bib0023","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.22.01064","article-title":"SOFT and TEXT Investigators and the International Breast Cancer Study Group (a division of ETOP IBCSG Partners Foundation). Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT","volume":"41","author":"Pagani","year":"2023","journal-title":"Trials J Clin Oncol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820923001702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820923001702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:25:12Z","timestamp":1761513912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820923001702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1526820923001702"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2023.06.013","relation":{},"ISSN":["1526-8209"],"issn-type":[{"type":"print","value":"1526-8209"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2023.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}